Corcept Therapeutics Inc $ 27.98 -0.65 (-2.27%)
Volume:
347,670
Avg Vol (1m):
744,145
Market Cap $:
3.25 Bil
Enterprise Value $:
2.82 Bil
P/E (TTM):
31.45
P/B:
6.64
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 141.47 | ||
| Equity-to-Asset | 0.92 | ||
| Debt-to-Equity | 0.01 | ||
| Debt-to-EBITDA | 0.02 | ||
| Piotroski F-Score | 7 | ||
| Altman Z-Score | 47.51 | ||
| Beneish M-Score | -3.09 | ||
| WACC vs ROIC | |||
Profitability Rank | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 37.27 | ||
| Net Margin % | 30.73 | ||
| ROE % | 26.57 | ||
| ROA % | 24.24 | ||
| ROC (Joel Greenblatt) % | 2385.29 | ||
| 3-Year Revenue Growth Rate | 52.9 | ||
| 3-Year EBITDA Growth Rate | 119.3 | ||
| 3-Year EPS without NRI Growth Rate | 122.4 |
CORT
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 31.45 | ||
| Forward PE Ratio | 39.43 | ||
| PE Ratio without NRI | 31.45 | ||
| Price-to-Owner-Earnings | 26.41 | ||
| PB Ratio | 6.64 | ||
| PS Ratio | 9.67 | ||
| Price-to-Free-Cash-Flow | 20.97 | ||
| Price-to-Operating-Cash-Flow | 20.84 | ||
| EV-to-EBIT | 21.28 | ||
| EV-to-EBITDA | 20.94 | ||
| EV-to-Revenue | 7.94 | ||
| Shiller PE Ratio | 225.4 | ||
| Current Ratio | 10.77 | ||
| Quick Ratio | 10.65 | ||
| Days Inventory | 325.66 | ||
| Days Sales Outstanding | 22.51 | ||
| Days Payable | 412.24 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.63 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 2.32 | ||
| Price-to-Graham-Number | 3.04 | ||
| Earnings Yield (Greenblatt) % | 4.69 |